Ranibizumab treatment improves the reading speed of patients with neovascular age-related macular degeneration: A nonrandomized clinical trial using the Radner reading chart.
Fiche publication
Date publication
novembre 2024
Journal
Journal francais d'ophtalmologie
Auteurs
Membres identifiés du Cancéropôle Est :
Dr GOETZ Christophe
Tous les auteurs :
Hayek G, Reglodi D, Goetz C, Perone JM, Csutak A
Lien Pubmed
Résumé
Intravitreal injections with anti-vascular endothelial growth factor (VEGF) drugs can slow progression in neovascular age-related macular degeneration (nAMD). Best spectacle-corrected visual acuity (BSCVA) and/or central retinal thickness (CRT) are common barometers of efficacy of this treatment. However, BSCVA does not accurately measure reading ability, which is often severely impacted by nAMD. Since most studies on the effect of intravitreal anti-VEGF injections on reading ability in nAMD have limitations, we conducted an open-label nonrandomized non-blinded self-controlled clinical trial using Radner Charts, a standardized, validated tool for measuring reading ability.
Mots clés
Analyse multivariée, BSCVA, Central retinal thickness, DMLA humide, Dégénérescence maculaire néovasculaire liée à l’âge, Injection intravitréenne d’anti-VEGF, Intravitreal anti-VEGF injection, Mots par minute, Multivariate analysis, Neovascular age-related macular degeneration, Radner Reading Chart, Ranibizumab, Reading speed, Tableau de lecture Radner, Vitesse de lecture, Wet AMD, Words per minute, nAMD, Épaisseur centrale de la rétine
Référence
J Fr Ophtalmol. 2024 11 5;48(1):104350